Poster Abstracts 24th

2017 Poster Abstracts

The deadline to submit an abstract for poster presentations has passed.

To inquire about submitting a late abstract please contact [email protected].

POSTER PRESENTATION INFORMATION

Each poster must be a minimum of 36″ x 48″ and cannot exceed 48″ (vertical) x 96″ (horizontal). Poster board assignments and details on poster set-up will be emailed to you in late September.

The Poster Session will be held in the Ambassador Ballroom on Thursday, October 5, 2017, from 8:30pm to 11:00pm. Posters will be arranged in alphabetical order by the presenting author’s last name. Copies of the poster on 11″ x 17″ paper can accompany the poster as handouts but cannot be mounted on the poster boards.

Posters can be set up any time after 12pm on Wednesday, October 4, 2017. All Posters must be removed from poster boards by 8am on Friday, October 6, 2017.

For poster presentation inquiries please contact [email protected] or (310) 570-4705.

POSTER ABSTRACTS

Author	Abstract Title
Abida, Wassim	Identifying mismatch repair-deficient prostate cancer for immune checkpoint therapy
Aggarwal, Rahul	Transferrin-based positron emission tomography detects MYC-positive prostate cancer
Alyamani, Mohammad	Pharmacokinetics of Biochemically Active Steroidal Metabolites of Abiraterone in Healthy Volunteers
Amend, Sarah	C1orf116, a gene of unknown function, inhibits the active migratory phenotype of lethal metastatic cancer cells by promoting an epithelial phenotype
Armstrong, Andrew	Convergent hormone therapy resistance mediated by stress/dormancy-like pathways in prostate cancer
Augello, Michael	Role of CHD1 in cistrome reprogramming and prostate cancer progression
Beltran, Himisha	Whole genome methylation of tumor biopsies and circulating tumor DNA in advanced prostate cancer
Bevan, Charlotte	Changing faces of FUS: FUS/TLS represses androgen receptor activity through disruption of the transcriptional complex
Bose, Rohit	Whole genome gene-silencing screens in prostate cancer metastasis-derived cells identify a commonly inactivated tumor suppressor, ERF, and suggest rationale drug combination strategies for targeted therapies.
Brennen, Nathaniel	Depleting Tumor-infiltrating Mesenchymal Stem Cells to Overcome the Immunosuppressive Microenvironment and Enhance Immunotherapy Efficacy in Prostate Cancer
Brooks, Nigel	Targeting the bromodomain of p300/CBP for the treatment of castration resistant prostate cancer
Campbell, Douglas	Glypican-1 as a novel immunotherapeutic target in prostate cancer
Carlo, Maria	Evaluating an alternative clinical genetics care delivery model for patients with prostate cancer
Castro, Elena	Phase II study of the Prednisone to Dexamethasone switch in mCRPC patients on Abiraterone plus Prednisone (SWITCH study).
Chan, Charles	Temporal/Spatial Transcriptomic analysis of Normal and Neoplastic Stem Cell Niches.
Cheng, Michael	Next-generation sequencing (NGS) of tissue and cell free DNA (cfDNA) to identify somatic and germline alterations in advanced prostate cancer.
Chu, Gina Chia Yi	Metastasis-initiating cells (MICs) recruit and reprogram bystander indolent cells to participate in prostate cancer progression and metastasis
Cox, Michael	Small molecule- and siRNA-based targeting of scavenger receptor BI in castration resistant prostate cancer
Cyrta, Joanna	Integrative genomics of prostate cancer progression: a pilot study
Davies, Alastair	Identity fraud: lineage plasticity as a mechanism of anti-androgen resistance and target for therapy
deLeeuw, Renee	Bypass kinase pathways lead to acquired CDK4/6 inhibitor resistance
Dondossola, Eleonora	Preclinical Targeting of Established Prostate Cancer Lesions in Bone by Radium-223: Impact on Tumor Cells and the Microenvironment
Downer, Mary	Moderate alcohol intake and risk of lethal prostate cancer in the Health Professionals Follow- up Study
Drake, Charles	Combining Intra-Tumoral Treg Depletion with Androgen Deprivation Therapy (ADT): Pre- Clinical Activity in the Myc-CaP Model of Prostate Cancer
Drake, Justin	Phosphoproteome-guided multi-omic integration prioritizes kinases to co-target with the androgen receptor for drug synergy in prostate cancer
Feldman, Adam	Urinary tissue inhibitor of metalloproteinase 1 as a novel biomarker to identify men with clinically significant prostate cancer.
Fletcher, Claire	Long Non-Coding RNAs Linking AR Activity and DNA Damage in Prostate Cancer
Garraway, Isla	Chromosomal instability in diagnostic prostate needle biopsies predicts metastatic disease
Goldkorn, Amir	Multi-parametric liquid biopsy analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and cell-free RNA (cfRNA) in metastatic castrate resistant prostate cancer (mCRPC)
Golsorkhi, Anthony	TRITON2: An International, Multicenter, Open-Label, Phase 2 Study of the PARP Inhibitor Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associated with Homologous Recombination Deficiency (HRD)
Goodrich, David	Rb1 loss, lineage plasticity, and antiandrogen resistance in prostate cancer
Gross, Mitchell	Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone acetate plus prednisone or enzalutamide
Gueron, Geraldine	Prostate cancer (PCa) candidate biomarkers identified by proteome profiling of formalin-fixed and paraffin-embedded PCa tissue sections
Haffner, Michael	AIM1 suppresses migration and metastatic dissemination in prostate cancer.
Hargrove, Amanda	Targeting the lncRNA SChLAP1 in aggressive prostate cancer by the assembly of multivalent small molecule inhibitors
Harmon, Stephanie	Correlation of architectural patterns of prostate cancer histology with multiparametric MRI appearance
He, Housheng	ONECUT2 Drives Neuroendocrine Prostate Cancer Through Hypoxia Signaling
Heaphy, Christopher	A high-throughput approach to measure cell type-specific telomere lengths in archival prostate tissues
Hearn, Jason	HSD3B1 Genotype and Response to Androgen Deprivation Therapy for Biochemical Recurrence after Radiotherapy for Localized Prostate Cancer
Hectors, Stefanie	Advanced diffusion-weighted imaging of prostate cancer: correlation with histopathology
Ippolito, Joseph	Unique Central Carbon Metabolism in Small Cell Prostate Cancer
Jain, Suneil	Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy
Jamieson, Christina	Understanding heterogeneity and drug resistance in 3D cultures of patient prostate cancer bone metastases and primagrafts
Jarrard, Dave	Metformin and Androgen Deprivation Therapy Improves Prostate Cancer Survival
Jones, Jeremy	Androgen Receptor DNA binding domain inhibitors to treat AR splice variant-driven prostate cancer
Joshua, Anthony	Patterns of failure on Ga PSMA (GaPSMA) and F18 FDG (FDG) PET CT in a prospective phase 2 trial of 177Lu DKFZ PSMA 617 (LuPSMA) in men with castrate resistant metastatic prostate cancer (mCRPC).
Kaittanis, Bambos	PSMA-targeting Clinical Nanocarriers for Patient-specific Treatment in Prostate Cancer
Karnes, R Jeffrey	Risk Stratification of Prostate Cancer in Needle Biopsy Specimens: Utilization of a Multi-gene FISH Panel
Klein, Eric	The Single Parameter, Structure-Based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High Grade Prostate Cancer Compared to a Concentration-Based Assay of Total PSA
Kloss, Christopher	TGFβ Signaling Blockade Enhances the Functionality of PSMA Targeted CAR Human T Cells for the Eradication of Metastatic Prostate Cancer
Knudsen, Beatrice	Quantitative Digital Image Analysis and Machine Learning for Staging of Prostate Cancer at Diagnosis
Kortylewski, Marcin	Systemic administration of CpG-STAT3 antisense oligonucleotides induces regression of two bone-localized prostate tumor models
Kothari, Vishal	Investigating DNAPK as a therapeutic target and a prognostic biomarker in castration- resistant prostate cancer.
Kyriakopoulos, Christos	A pilot trial of neoadjuvant chemohormonal therapy with PSMA PET directed dissection of prostatectomy specimens for analysis of the tumor microenvironment
Labbe, David	TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup
Lack, Nathan	Androgen receptor binding causes increased mutations in prostate cancer
Lam, Hung-Ming	Beyond androgen-deprivation therapy: High-dose testosterone as a potential therapy in enzalutamide-resistant prostate cancer
Larman, Ben	Multiplexed analysis of fixed tissue RNA using Ligation in situ Hybridization
Lee, John	Targeting CEACAM5 as a tumor-associated surface antigen in neuroendocrine prostate cancer
Li, Wenliang	Beta adrenergic signaling, neuroendocrine differentiation and angiogenesis in prostate cancer progression.
Li, Zhenfei	Galeterone metabolism in castration resistant prostate cancer
Linder, Karen	Impact of ¹⁸F-fluciclovine PET/CT on clinical management of patients with recurrent prostate cancer: results from the Phase III FALCON trial
Loeb, Stacy	Crowd-Funding for Prostate Cancer
Long, Tiha	Glucocorticoid receptor activation regulates both androgen receptor (AR)-dependent and independent cancer-related genes following AR blockade
Lupold, Shawn	Mesenchymal compartmentalization of miR-1 and miR-143 in prostate tissue and loss of expression in tumor-associated stroma
Macias, Everardo	RIOK2 IS A MEDIATOR OF OBESITY ENHANCED PROSTATE CANCER GROWTH
Madan, Ravi	Combining Immune Checkpoint Inhibition (Ipilimumab and Nivolumab) with a Therapeutic Cancer Vaccine (Prostvac) in Prostate Cancer
Mahajan, Nupam	Targeting Androgen Receptor and ACK1 signaling with Novel Epigenetic Therapeutics in Castration-Resistant Prostate Cancer
Malek, Reem	TWIST1-mediated regulation of HOXA9 promotes resistance to PARPi in Prostate Cancer
Markowski, Mark	NOVEL DRUG COMBINATIONS WITH BETI IN AN AR-INDEPENDENT MODEL OF PROSTATE CANCER
Mateo, Joaquin	ATM loss in metastatic prostate cancer
McArt, Darragh	Integrative analytics for precision medicine
McKay, Rana	A phase II trial of abiraterone acetate (AA) without prednisone in castration resistant prostate cancer (CRPC): Results of circulating mineralocorticoid and androgen levels.
Mitrofanova, Antonina	Integrative (epi) genomic analysis predicts response to anti-androgen therapy in prostate cancer
Miyamoto, David	An RNA-based digital circulating tumor cell signature is predictive of drug response and early dissemination in prostate cancer
Montie, Heather	Androgen receptor acetylation modulates proliferation of castrate-resistant prostate cancer
Moreno, Carlos	Identification of key transcription factor target interactions that regulate prostate cancer responses to Androgen Deprivation Therapy and Metastasis
Mustonen, Mika	ODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration- resistant prostate cancer
Neeb, Antje	Targeting the co-chaperone Bag-1L as a new strategy to inhibit the N-terminal AF-1 domain of the androgen receptor in castration resistant prostate cancer
Nickols, Nicholas	68Ga-PSMA PET/CT mapping of early biochemical recurrence after primary surgery in 270 patients: Impact on Salvage Radiotherapy Planning
Niknafs, Yashar	The Landscape of Long Non-Coding RNAs in Metastatic Prostate Cancer
Olmos, David	PROREPAIR-B: A prospective cohort study of DNA repair defects in mCRPC
O’Neill, Vincent	Synergy Between BXCL701, a DPP Inhibitor, and Immune Checkpoint Inhibitors Discovered Using AI and Big Data Analytics
Pachynski, Russell	Personalizing Combinatorial Prostate Cancer Immunotherapy
Parsons, Kellogg	The Men’s Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): Recruitment Feasibility and Baseline Demographics of a Randomized Trial of Diet in Men on Active Surveillance for Prostate Cancer
Patnaik, Akash	Prostate Cancers Harbor Mutually Exclusive Genomic Drivers That Are Enriched Within Non-T cell Inflamed Tumors
Posadas, Edwin	Gene Expression Analysis in Circulating Tumor Cells from Prostate Cancer Patients using the NanoVelcro Assay
Preston, Mark	Prostate-specific antigen levels in men aged 60‒70 and development of lethal prostate cancer over 30 years: Implications for risk-stratified screening
Puca, Loredana	Rovalpituzumab tesirine (Rova-T) as a therapeutic agent for neuroendocrine prostate cancer
Qiao, Yuanyuan	Development of a Novel Autophagy Inducing Multi-Kinase Inhibitor for the Treatment of Castration Resistant Prostate Cancer
Quigley, David	Analysis of circulating cell-free DNA identifies multi-clonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors
Raj, Ganesh	Androgen Receptor Variants Mediate DNA Repair Following Radiation in Prostate Cancer
Reder, Nicholas	3D light-sheet microscopy for next generation prostate pathology
Rider, Jennifer	Androgen Receptor Activity in Prostate Tumors from HIV-infected and HIV-uninfected Men
Rodeck, Ulrich	Molecular signatures of combination immunotherapy of prostate cancer using a Listeria-based PSA vaccine and radiation
Rodrigues, Daniel	RB1 Depletion in Metastatic Castration Resistant Prostate Cancer: Novel Genomic Mechanisms and Clinical Impact
Ryan, Charles	TRITON3: An International, Randomized, Open-Label, Phase 3 Study of the PARP Inhibitor Rucaparib vs Physician’s Choice of Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associated with Homologous Recombination Deficiency (HRD)
Salami, Simpa	Molecular dissection of magnetic resonance imaging visible and invisible prostate cancer: Biological insights and therapeutic implications
Schiewer, Matthew	PARP-1 and E2F1 collaborate to transcriptionally regulate DNA repair factor availability
Schweizer, Michael	Cell-free Circulating Tumor DNA is a Reliable Specimen for Mutation Profiling in Prostate Cancer Patients with High-Burden Disease
Shafi, Ayesha	Leveraging the PDeX (Patient Derived eXplant) model to determine the basis for response to AR-directed therapeutics in prostate cancer
Shi, Jinjun	Nucleic Acid Nanotherapeutics for Prostate Cancer
Simons, Brian	A prostate tumor neo-antigen polyionic virus-like particle vaccine shows immunogenicity and efficacy in a mouse model of advanced prostate cancer
Smith, Bryan	Stem cell directed pan cancer analysis reveals a human adult stem cell signature that defines aggressive epithelial cancer subtypes
Sowalsky, Adam	Prostate cancer neoadjuvant intensive androgen deprivation therapy selects for tumor foci with diverse oncogenic alterations
Stopsack, Konrad	Identifying cholesterol-dependent prostate cancers treatable with statins
Stoyanova, Tanya	Trop2 as a new driver of castration-resistant prostate cancer
Tien, Jean	Androgen receptor-regulated long non-coding RNA 1 is a novel prostate cancer oncogene and therapeutic target
Traka, Maria	Increased transcriptional and metabolic capacity for lipid metabolism in the peripheral zone of the prostate may underpin its increased susceptibility to cancer.
Tran, Phuoc	Interim results from a phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)
Trinh, Quoc-Dien	NON-ALCOHOLIC FATTY LIVER DISEASE IN MEN UNDERGOING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER
Tsai, Hung-Ji	Targeting karyotypic heterogeneity in aneuploid populations
VanBrocklin, Henry	PSMA-targeted PET imaging and radionuclide therapy for prostate cancer: Development of a platform agent.
VanderWeele, David	Integrative genomic analysis of coincident cancer foci implicates PTEN alterations in ductal adenocarcinoma of the prostate
Viswanathan, Srinivas	Functional genetic and genomic approaches to studying androgen receptor splicing and therapy resistance in castration-resistant prostate cancer
Viswanathan, Vasanthi	A therapy-resistant state of cancer cells relevant to neuroendocrine prostate cancer is susceptible to ferroptotic cell death
Walsh, Bradley	Evaluation of the MiCheck® MIA test performance in differentiating aggressive from non- aggressive prostate cancer – the MiCheck-01 prospective trial
Wang, Shaomeng	Small-Molecule Degrades of the BET Bromodoman Proteins as New Prostate Cancer Therapeutics
Wang, Yu	TARGETING NONO-PSPC1 IN METASTATIC PROSTATE CANCER
Yamoah, Kosj	Distinct AR dependent transcriptional program in ETS fusion negative prostate cancer
Yadav, Kamlesh	Clinical utility of Pseudouridine as a diagnostic Biomarker to detect Prostate Cancer
Yang, Rendong	Deciphering AR genomic rearrangements in prostate cancer
Zarif, Jelani	TARGETING M2-TUMOR ASSOCIATED MACROPHAGES IN PROSTATE CANCER USING SURFACE ENRICHED GLYCOPROTEINS
Zhao, Di	Synthetic essentiality of chromatin remodeling factor CHD1 in PTEN deficient cancer
Zhao, Shuang	The immune landscape of prostate cancer

https://www.pcf.org/scientific-retreat/24th-annual/poster-abstracts/